Year archive

DR REDDYS LABORATORIES LTD — 2022 filings

All 261 regulatory filings released by DR REDDYS LABORATORIES LTD (RDY) in 2022, sourced directly from the official regulator.

261 Filings

2022 Period

2022 filings (261)

Filing	Released	Lang
FORM 6-K Regulatory Filings	2022-12-29	English
Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Legal Proceedings Report	2022-12-29	English
FORM 6-K Regulatory Filings	2022-12-27	English
The trading window for dealing in securities of the Company will be closed from December 31, 2022, to January 27, 2023 (both days inclusive). Board/Management Information	2022-12-27	English
DR.REDDY''s LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/01/2023 ,inter alia, to consider and approve A meeting of the .... Regulatory Filings	2022-12-27	English
FORM 6-K Regulatory Filings	2022-12-27	English
Copy of Newspaper Publication- Loss of Share Certificates Regulatory Filings	2022-12-26	English
Intimation regarding completion of transaction for sale of our wholly owned subsidiary Dr. Reddy''s Research and Development B. V. (DRRDBV)''s certain assets and liabilities including transfer .... Capital/Financing Update	2022-12-23	English
FORM 6-K Regulatory Filings	2022-12-19	English
Press Release titled ''Dr. Reddy's successfully completes Phase 1 study of DRL_TC, a proposed biosimilar of tocilizumab'' Regulatory Filings	2022-12-19	English
6-K Filing Regulatory Filings	2022-12-19	English
Dr. Reddy''s Research and Development B. V., a wholly owned subsidiary of the Company, has entered into an Asset Purchase Agreement for sale of its certain assets and liabilities including .... Capital/Financing Update	2022-12-17	English
FORM 6-K Regulatory Filings	2022-12-16	English
Allotment of Equity Shares on exercise of Stock Options under ESOPs Share Issue/Capital Change	2022-12-16	English
Aurigene Oncology Limited, a wholly owned subsidiary of Dr. Reddy''s Laboratories Limited, reports results of AUR101 in Phase II Study in Patients with moderate to severe psoriasis Regulatory Filings	2022-12-16	English
Issue of Letter of Confirmation/Share certificate(s) in lieu of share certificate(s) reported lost/misplaced Regulatory Filings	2022-12-12	English
FORM 6-K Regulatory Filings	2022-12-07	English
Intimation about group investor meeting Regulatory Filings	2022-12-06	English
FORM 6-K Regulatory Filings	2022-11-28	English
Sustainability Report for FY2022 Environmental & Social Information	2022-11-24	English
Loss of Share certiifcates Regulatory Filings	2022-11-23	English
FORM 6-K Regulatory Filings	2022-11-22	English
Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Legal Proceedings Report	2022-11-22	English
Copy of Newspaper Publication- Loss of Share Certificates Regulatory Filings	2022-11-17	English
This is to inform you that the Company's management will be participating in the conferences and group meetings, as attached. Regulatory Filings	2022-11-16	English
6-K Filing Regulatory Filings	2022-11-16	English
Disclosure of Related Party Transactions for H1 FY23 Regulatory Filings	2022-11-11	English
FORM 6-K Regulatory Filings	2022-11-03	English
Transcript of the Earnings call conducted on October 28, 2022 Call Transcript	2022-11-03	English
FORM 6-K Regulatory Filings	2022-11-02	English
Intimation regarding Schedule of Analyst / Institutional Investor Meetings Investor Presentation	2022-11-01	English
FORM 6-K Regulatory Filings	2022-10-31	English
FORM 6-K Regulatory Filings	2022-10-31	English
Copy of Newspaper Publication Q2 FY23 financial results Interim / Quarterly Report H1 2023	2022-10-31	English
Intimation regarding end of term of Mr Prasad Menon, as a Director of the Company, from close of business hours on October 29, 2022, on completion of his term as an Independent Director .... Board/Management Information	2022-10-29	English
This is to inform you that the Company has filed its unaudited condensed consolidated interim financial statements prepared under IFRS in Form 6-K for the quarter ended September 30, 2022, .... Interim / Quarterly Report Q2 2023	2022-10-29	English
Intimation of audio recording of Earnings call held on October 28, 2022 Regulatory Filings	2022-10-29	English
FORM 6-K Earnings Release	2022-10-28	English
FORM 6-K Interim / Quarterly Report	2022-10-28	English
Issue of Letter of Confirmation in lieu of share certificate(s) reported lost/misplaced Regulatory Filings	2022-10-28	English
Outcome of Board Meeting - Unaudited Financial Results for the quarter and half-year ended September 30, 2022 Interim / Quarterly Report	2022-10-28	English
Disclosure under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 Share Issue/Capital Change	2022-10-28	English
FORM 6-K Regulatory Filings	2022-10-24	English
Results of voting through Postal Ballot pursuant to Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for appointment of Mr. Arun Madhavan .... Declaration of Voting Results & Voting Rights Announcements	2022-10-21	English
Earnings Call Notification: Q2 FY23 Regulatory Filings	2022-10-13	English
Copy of Newspaper Publication- Loss of Share Certificates Regulatory Filings	2022-10-13	English
6-K Filing Regulatory Filings	2022-10-13	English
Press Release on ''World Economic Forum recognises Dr. Reddy's Hyderabad factory as part of its Global Lighthouse Network'' Regulatory Filings	2022-10-11	English
6-K Filing Regulatory Filings	2022-10-11	English
Allotment of Equity Shares on exercise of Stock Options under ESOPs Share Issue/Capital Change	2022-10-07	English
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India Major Shareholding Notification	2022-10-03	English
Allotment of Equity Shares on exercise of Stock Options under ESOPs Share Issue/Capital Change	2022-09-30	English
FORM 6-K Regulatory Filings	2022-09-29	English
The trading window for dealing in securities of the Company will be closed from Friday, September 30, 2022, to Sunday, October 30, 2022 (both days inclusive). Regulatory Filings	2022-09-28	English
DR.REDDY''s LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2022 ,inter alia, to consider and approve the Unaudited Financial .... Board/Management Information	2022-09-28	English
Intimation of Loss of Share certificate(s) Regulatory Filings	2022-09-28	English
FORM 6-K Regulatory Filings	2022-09-27	English
Intimation regarding investors group discussions Regulatory Filings	2022-09-27	English
FORM 6-K Regulatory Filings	2022-09-23	English
Intimation with copies of newspaper ad published for postal ballot Regulatory Filings	2022-09-22	English
FORM 6-K Regulatory Filings	2022-09-20	English
Intimation regarding despatch of postal ballot notice Proxy Solicitation & Information Statement	2022-09-20	English
FORM 6-K Regulatory Filings	2022-09-19	English
Intimation for allotment of shares pursuant to ESOP Share Issue/Capital Change	2022-09-17	English
Issue of Letter of Confirmation in lieu of share certificate(s) reported lost/misplaced Regulatory Filings	2022-09-16	English
FORM 6-K Regulatory Filings	2022-09-12	English
Intimation Regulatory Filings	2022-09-10	English
FORM 6-K Regulatory Filings	2022-09-08	English
Dr. Reddy''s Laboratories announces the launch of Lenalidomide Capsules in the U.S. with two of six strengths eligible for first-to-market, 180-day exclusivity. Regulatory Filings	2022-09-07	English
Intimation of loss of share certificate Regulatory Filings	2022-09-07	English
FORM 6-K Regulatory Filings	2022-09-07	English
Schedule of Analyst / Institutional Investor Meetings Regulatory Filings	2022-09-06	English
The Exchange had sought clarification from Dr Reddys Laboratories Ltd with respect to news article appearing on https://www.thehindubusinessline.com/companies/dr-reddys-aurigene-ink-mou-with-dndi-on-n Regulatory Filings	2022-09-02	English
BRSR FY2022 Environmental & Social Information	2022-09-01	English
FORM 6-K Regulatory Filings	2022-08-26	English
Intimation Regulatory Filings	2022-08-25	English
EXHIBIT 6-K Regulatory Filings	2022-08-25	English
Loss of Share Certificates Regulatory Filings	2022-08-25	English
intimation Regulatory Filings	2022-08-24	English
Copies of newspaper publication-Loss of share certificate Regulatory Filings	2022-08-22	English
Disclosure of related party transactions for H2FY22 Regulatory Filings	2022-08-17	English
FORM 6-K Regulatory Filings	2022-08-08	English
Intimation Regulatory Filings	2022-08-06	English
FORM 6-K Regulatory Filings	2022-08-03	English
Issue of Duplicate Share certiifcate Regulatory Filings	2022-08-03	English
Earnings call Transcript Q1 FY23 Regulatory Filings	2022-08-03	English
FORM 6-K Board/Management Information	2022-08-01	English
Dr. Bruce Carter ceased to be a Director of the Company, on July 30, 2022, on account of completion of his second term as an Independent Director. Board/Management Information	2022-08-01	English
FORM 6-K Regulatory Filings	2022-08-01	English
FORM 6-K Regulatory Filings	2022-08-01	English
Newspaper publication for unaudited financial results for Q1 FY23 Regulatory Filings	2022-07-30	English
Sale of investment in wholly-owned subsidiary - Imperial Credit Private Limited Capital/Financing Update	2022-07-30	English
Dr. Reddy''s Laboratories enters into a licensing agreement with Slayback Pharma to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify® in the U.S. Capital/Financing Update	2022-07-29	English
Consolidated Scrutinizer''s Report Declaration of Voting Results & Voting Rights Announcements	2022-07-29	English
Outcome of 38th Annual General Meeting & Voting results. Declaration of Voting Results & Voting Rights Announcements	2022-07-29	English
Filing of Form 6K for Q 1 FY23 with SEC Interim / Quarterly Report Q1 2023	2022-07-29	English
Audio Recordings of the Earnings call conducted on July 28, 2022. Regulatory Filings	2022-07-29	English
FORM 6-K Board/Management Information	2022-07-29	English
FORM 6-K Interim / Quarterly Report	2022-07-28	English
FORM 6-K Interim / Quarterly Report	2022-07-28	English
Unaudited Financial Results for the quarter ended June 30, 2022 Interim / Quarterly Report Q1 2023	2022-07-28	English
Grant of Stock Options to the eligible employees under the Employee Stock Options Schemes of the Company. Share Issue/Capital Change	2022-07-28	English
Allotment of 7,426 equity shares of Rs. 5/- each of the Company, fully paid up. Share Issue/Capital Change	2022-07-28	English
Appointment of Mr. Arun Madhavan Kumar (DIN: 09665138) as an Additional Director, categorized as Independent, on the Board of the Company. Board/Management Information	2022-07-28	English
Appointment of Mr. Arun Madhavan Kumar (DIN: 09665138) as an Additional Director, categorized as Independent, on the Board of the Company. Board/Management Information	2022-07-28	English
Unaudited Financial Results for the quarter ended June 30, 2022 Interim / Quarterly Report Q1 2023	2022-07-28	English
FORM 6-K Regulatory Filings	2022-07-27	English
Dr. Reddy''s Laboratories announces the launch of Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market Capital/Financing Update	2022-07-27	English
FORM 6-K Regulatory Filings	2022-07-22	English
Dr. Reddy's announces the first-to-market launch of over-the-counter, store-brand equivalent of Allegra-D® 24 HR in the U.S. Market Regulatory Filings	2022-07-22	English
FORM 6-K Regulatory Filings	2022-07-14	English
Earnings call notification for Q1 FY23 Call Transcript	2022-07-13	English
FORM 6-K Regulatory Filings	2022-07-12	English
Newspaper advertisement for notice of AGM and evoting instructions AGM Information	2022-07-11	English
Dr. Reddy''s Laboratories announces the launch of Fesoterodine Fumarate Extended-Release Tablets in the U.S. market Regulatory Filings	2022-07-08	English
6-K Filing Regulatory Filings	2022-07-08	English
FORM 6-K Regulatory Filings	2022-07-07	English
Intimation Regulatory Filings	2022-07-07	English
FORM 6-K Regulatory Filings	2022-07-07	English
Annual Report 2021-22 Annual Report FY 2022	2022-07-06	English
Notice of 38th Annual General Meeting (AGM) and Annual Report 2021-22 Annual Report FY 2022	2022-07-06	English
FORM 6-K Regulatory Filings	2022-06-30	English
Updates Regulatory Filings	2022-06-29	English
The trading window for dealing in securities of the Company will be closed from Thursday, June 30, 2022, to Saturday, July 30, 2022 (both days inclusive). Regulatory Filings	2022-06-29	English
DR.REDDY''s LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2022 ,inter alia, to consider and approve To consider and approve .... Regulatory Filings	2022-06-29	English
FORM 6-K Report Publication Announcement	2022-06-28	English
Transcript of Investor Day Regulatory Filings	2022-06-28	English
Dr. Reddy's Laboratories Limited announces filing of Annual Report on Form 20-F Report Publication Announcement	2022-06-28	English
FORM 20-F Annual Report FY 2022	2022-06-27	English
Copy of newspaper publication Regulatory Filings	2022-06-27	English
FORM 6-K Regulatory Filings	2022-06-24	English
Dr. Reddy''s Laboratories announces the acquisition of an injectable product portfolio from Eton Pharma Capital/Financing Update	2022-06-24	English
Intimation - Settlement Agreement with respect to buprenorphine and naloxone sublingual film Regulatory Filings	2022-06-24	English
Allotment of Equity Shares on exercise of stock options under ESOPs Share Issue/Capital Change	2022-06-23	English
FORM 6-K Regulatory Filings	2022-06-22	English
Investor day presentation Investor Presentation	2022-06-21	English
FORM 6-K Regulatory Filings	2022-06-21	English
6-K Filing Regulatory Filings	2022-06-21	English
Newspaper Publication for AGM date and book closure AGM Information	2022-06-20	English
Intimation regarding the communication as sent to all the shareholders with respect to the deduction of tax at source on dividend pay-out. Regulatory Filings	2022-06-17	English
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India Major Shareholding Notification	2022-06-16	English
FORM 6-K Regulatory Filings	2022-06-14	English
Dr. Reddy''s Laboratories announces the launch of the generic version of Nexavar (sorafenib) Tablets, USP, 200 mg in the U.S. market Regulatory Filings	2022-06-14	English
FORM 6-K Regulatory Filings	2022-06-13	English
Intimation about investor day on June 21, 2022 Investor Presentation	2022-06-13	English
FORM 6-K Regulatory Filings	2022-06-09	English
Press Release Capital/Financing Update	2022-06-09	English
FORM 6-K Regulatory Filings	2022-06-03	English
Intimation under Regulation 30 of the Listing Regulations regarding Schedule of Analyst / Institutional Investor Meetings Regulatory Filings	2022-06-03	English
FORM 6-K Regulatory Filings	2022-06-03	English
Disclosure of related party transactions for H2 FY22 under Regulation 23 Interim / Quarterly Report H2 2022	2022-06-02	English
FORM 6-K Regulatory Filings	2022-05-31	English
Dr. Reddy''s Laboratories announces the launch of Pemetrexed for Injection USP, in the U.S. Market Capital/Financing Update	2022-05-27	English
Newspaper publication Regulatory Filings	2022-05-27	English
Issue of Duplicate share certificate Share Issue/Capital Change	2022-05-27	English
Annual Secretarial compliance report for the year ended March 31, 2022 Regulatory Filings	2022-05-27	English
Loss of share certificates Regulatory Filings	2022-05-25	English
FORM 6-K Regulatory Filings	2022-05-24	English
Dr. Reddy''s Laboratories and Senores Pharmaceuticals, Inc. announce the launch Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. market Regulatory Filings	2022-05-24	English
Earnings call transcript for Q4 FY22 Call Transcript	2022-05-24	English
6-K Filing Regulatory Filings	2022-05-24	English
6-K Filing Regulatory Filings	2022-05-23	English
Newspaper advertisement regarding audited financial results for the quarter and year ended March 31, 2022 Earnings Release FY 2022	2022-05-20	English
Board Approval for re-appointment of Mr. K Satish Reddy, as a Whole-time Director, designated as Chairman Board/Management Information	2022-05-20	English
Grant of Employee Stock Options Board/Management Information	2022-05-20	English
The Register of Members and the Share Transfer Books of the Company shall remain closed from Wednesday, July 13, 2022 to Friday, July 15, 2022 (both days inclusive) for the purpose of the .... Board/Management Information	2022-05-20	English
38th Annual General Meeting (AGM) of the members of the Company on Friday, July 29, 2022. Board/Management Information	2022-05-20	English
The presentation and the audio recording of the earnings call for the quarter and financial year ended March 31, 2022 is available on Company''s website. Regulatory Filings	2022-05-20	English
Updates Board/Management Information	2022-05-20	English
FORM 6-K Regulatory Filings	2022-05-20	English
FORM 6-K Earnings Release	2022-05-19	English
The Board recommended a final dividend of Rs.30/- (600%) per equity share of Rs. 5/- each for the financial year 2021-22. Annual Report FY 2022	2022-05-19	English
Dr Reddys Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 19, 2022, inter alia, has recommended a final dividend of Rs. 30/- (600%) .... Annual Report FY 2022	2022-05-19	English
Results - Audited Financial Results for the year ended March 31, 2022. Earnings Release FY 2022	2022-05-19	English
Outcome of Board Meeting held on May 19, 2022 Annual Report FY 2022	2022-05-19	English
FORM 6-K Regulatory Filings	2022-05-11	English
Dr. Reddy's Laboratories enters into exclusive partnership with HK inno.N Corporation to commercialise novel molecule Tegoprazan in India & select Emerging Markets Capital/Financing Update	2022-05-11	English
AMENDMENT NO. 4 TO SCHEDULE 13D Major Shareholding Notification	2022-05-02	English
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details .... Capital/Financing Update	2022-04-29	English
FORM 6-K Regulatory Filings	2022-04-25	English
Intimation regarding Earnings call for Q4 and FY22 Regulatory Filings	2022-04-25	English
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Anuradha Gunupati & Others Major Shareholding Notification	2022-04-25	English
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Anuradha Gunupati & Others Major Shareholding Notification	2022-04-25	English
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Anuradha Gunupati & Others Major Shareholding Notification	2022-04-25	English
FORM 6-K Regulatory Filings	2022-04-22	English
Intimation of allotment, pursuant to merger Capital/Financing Update	2022-04-22	English
EXHIBIT 6-K Regulatory Filings	2022-04-20	English
Dr. Reddy''s Laboratories announces the launch of Posaconazole Delayed-Release Tablets in the U.S. Market Regulatory Filings	2022-04-20	English
Pursuant to Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that activities in relation .... Regulatory Filings	2022-04-19	English
We are enclosing herewith a copy of the yearly Compliance Certificate issued by the Company Secretary in Practice for the period from April 1, 2021 to March 31, 2022 under Regulation 40(9) .... Regulatory Filings	2022-04-19	English
FORM 6-K Regulatory Filings	2022-04-11	English
Intimation for effective date of Scheme of merger Regulatory Filings	2022-04-08	English
FORM 6-K Regulatory Filings	2022-04-08	English
Intimation of the Record Date for the issuance and allotment of its equity shares pursuant to the Scheme Capital/Financing Update	2022-04-08	English
FORM 6-K Regulatory Filings	2022-04-07	English
Intimation regarding approval of the Scheme of Amalgamation and Arrangement Capital/Financing Update	2022-04-07	English
Details of loss of share certificate Regulatory Filings	2022-04-06	English
FORM 6-K Regulatory Filings	2022-04-05	English
Dr. Reddy''s Laboratories announces the launch of Methylprednisolone Sodium Succinate for Injection, USP in the U.S. Market Regulatory Filings	2022-04-05	English
The Exchange had sought clarification from Dr Reddys Laboratories Ltd with respect to news article appearing on https://economictimes.indiatimes.com dated March 31, 2022 titled "Himachal .... Regulatory Filings	2022-04-05	English
FORM 6-K Regulatory Filings	2022-04-01	English
Intimation Capital/Financing Update	2022-04-01	English
FORM 6K Regulatory Filings	2022-03-29	English
Result of Postal Ballot Declaration of Voting Results & Voting Rights Announcements	2022-03-29	English
Dr Reddys Laboratories Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 19, 2022, inter alia, to consider and approve the Audited Standalone .... Board/Management Information	2022-03-29	English
Intimation on closure of trading window for board meeting scheduled on May 19, 2022 Board/Management Information	2022-03-29	English
DR.REDDY''s LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2022 ,inter alia, to consider and approve to consider and approve .... Board/Management Information	2022-03-29	English
FORM 6-K Regulatory Filings	2022-03-17	English
FORM 6-K Regulatory Filings	2022-03-17	English
Allotment of Equity Shares on exercise of ESOP Share Issue/Capital Change	2022-03-17	English
Cessation of Mr. Vivek Mittal as interim Compliance Officer w.e.f. March 17, 2022 on account of appointment of Mr. K Randhir Singh as Company Secretary and Compliance Officer. Board/Management Information	2022-03-17	English
Appointment of Company Secretary and Compliance Officer Board/Management Information	2022-03-17	English
FORM 6-K Regulatory Filings	2022-02-28	English
Newspaper publication regarding despatch of postal ballot notice and e-voting information Declaration of Voting Results & Voting Rights Announcements	2022-02-28	English
FORM 6-K Regulatory Filings	2022-02-25	English
Notice of Despatch of Postal ballot Proxy Solicitation & Information Statement	2022-02-25	English
Press Release Capital/Financing Update	2022-02-25	English
6-K Filing Regulatory Filings	2022-02-25	English
FORM 6-K Regulatory Filings	2022-02-22	English
Intimation Regulatory Filings	2022-02-21	English
Press Release M&A Activity	2022-02-21	English
Newspaper Publication Regulatory Filings	2022-02-18	English
Intimation Regulatory Filings	2022-02-16	English
FORM 6-K Regulatory Filings	2022-02-14	English
Intimation Regulatory Filings	2022-02-14	English
FORM 6-K Regulatory Filings	2022-02-11	English
Press Release Capital/Financing Update	2022-02-11	English
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation Of India Major Shareholding Notification	2022-02-11	English
FORM 6-K Regulatory Filings	2022-02-09	English
Intimation Regulatory Filings	2022-02-09	English
FORM 6-K Regulatory Filings	2022-02-09	English
Press Release Regulatory Filings	2022-02-09	English
FORM 6-K Regulatory Filings	2022-02-09	English
Update to Press Release M&A Activity	2022-02-08	English
FORM 6-K Regulatory Filings	2022-02-07	English
Press Release Regulatory Filings	2022-02-07	English
FORM 6-K Regulatory Filings	2022-02-03	English
Press Release M&A Activity	2022-02-03	English
FORM 6-K Regulatory Filings	2022-02-02	English
Press Release Environmental & Social Information	2022-02-02	English
FORM 6-K Regulatory Filings	2022-02-01	English
Intimation on Earnings call transcript and audio Call Transcript	2022-02-01	English
6-K Filing Regulatory Filings	2022-01-31	English
Newspaper ad for Q3 FY22 financials Earnings Release 9M 2022	2022-01-30	English
Intimation regarding filing of Form 6k Interim / Quarterly Report Q3 2022	2022-01-29	English
FORM 6-K Board/Management Information	2022-01-28	English
FORM 6-K Regulatory Filings	2022-01-28	English
FORM 6-K Interim / Quarterly Report	2022-01-28	English
ESOP Allotment intimation Share Issue/Capital Change	2022-01-28	English
Appointment of Ms. Pennv Wan (DIN: 09479493) as an Additional Director, categorized as Independent, on the Board of the Company. Board/Management Information	2022-01-28	English
Outcome of Board Meeting - Unaudited Financial Results for the quarter and nine months ended December 31, 2021. Interim / Quarterly Report	2022-01-28	English
Issue of Duplicate Share Certificate Regulatory Filings	2022-01-22	English
FORM 6-K Regulatory Filings	2022-01-18	English
Grant Of Stock Options Remuneration Information	2022-01-18	English
6-K Filing Regulatory Filings	2022-01-18	English
earnings call Regulatory Filings	2022-01-17	English
earnings call Earnings Release Q3 2022	2022-01-17	English
FORM 6-K Regulatory Filings	2022-01-10	English
Intimation Investor Presentation	2022-01-10	English
FORM 6-K Regulatory Filings	2022-01-07	English
Intimation regarding appointment of Dr. K P Krishnan as an Independent Director Board/Management Information	2022-01-07	English

Filings by year

2026 133 filings
2025 283 filings
2024 402 filings
2023 273 filings
2022 261 filings
2021 208 filings
2020 249 filings
2019 235 filings
2018 77 filings
2017 54 filings
2016 42 filings
2015 23 filings
2014 20 filings
2013 25 filings
2012 18 filings
2011 16 filings
2010 17 filings